Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Niox Group reports solid growth in final results
(Sharecast News) - Niox Group reported a robust 18% increase in revenue in its final results on Tuesday, amounting to £36.8m compared to £31.3m in the prior year. The AIM-traded firm said when adjusted for currency fluctuations, that growth surged to an impressive 22%.
Clinical revenue demonstrated substantial growth of 24%, reaching £32.6m, up from £26.2m in 2022.
The group's adjusted EBITDA stood at £11.4m, aligning with upgraded consensus estimates and marking a significant progression from £7.3m in 2022.
Niox also maintained a healthy net cash position of £19.9m at year-end on 31 December.
Shareholders were rewarded with a special dividend of 2.5p per share, totaling £10.5m, disbursed on 15 September, with the board proposing a final dividend of 1p per share.
Operationally, Niox established a new commercial organisation and distributor network in the US during the year, with a focus on enhancing revenues within primary care settings.
Furthermore, efforts to strengthen market presence were evident through the expansion of the distributor network in the EMEA and APAC regions.
Development for Niox Pro, the next-generation device tailored for clinical professionals, was started, as the company achieved a significant milestone with a $3.5m payment received from Beyond Air in August, with a final payment of $4.5m expected by August this year, along with potential royalty payments of up to $6m thereafter.
"Management is continuing to implement the strategy of deepening and broadening global distribution, which coupled with outsourcing sales and manufacturing is expected to drive further profitable growth," said executive chairman Ian Johnson.
"Whilst the current focus is on growing sales in primary care, looking ahead, the company plans to introduce FeNO testing in other healthcare channels such a pharmacies and occupational health and ultimately to launch a product for use by patients to manage their condition at home."
Johnson said the group had made a positive start to 2024, and continued to be highly cash generative, with cash of £22.4m on 29 February.
"The company has a robust strategy in place to expand the business and generate profitable growth from the large underserved target market and has the financial resources to achieve its objectives and further enhance shareholder value."
At 1400 GMT, shares in Niox Group were up 1.39% at 65.7p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.